Union Bancaire Privee UBP SA Makes New Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Union Bancaire Privee UBP SA purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 4th quarter, HoldingsChannel reports. The firm purchased 5,485 shares of the financial services provider’s stock, valued at approximately $693,000.

Several other large investors also recently bought and sold shares of IBB. Darwin Wealth Management LLC purchased a new stake in iShares Biotechnology ETF during the 3rd quarter worth about $29,000. Highline Wealth Partners LLC purchased a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $30,000. HHM Wealth Advisors LLC increased its holdings in shares of iShares Biotechnology ETF by 200.0% in the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at about $33,000. Finally, Hager Investment Management Services LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 0.1 %

IBB opened at $138.74 on Tuesday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The business’s 50-day simple moving average is $135.64 and its 200-day simple moving average is $140.77.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.